Medroxyprogesterone acetate and Estradiol cypionate injection |
Lunelle |
Clinical Trial: An evaluation of safety and efficacy of Anecortave Acetate vs. placebo in patients with subfoveal choroidal neovascularization(CNV) due to wet age-related macular degeneration(AMD)
This study is currently recruiting patients.
|
Purpose
To demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Macular Degeneration Maculopathy, Age-Related Age-Related Maculopathies Age-Related Maculopathy Maculopathies, Age-Related | Drug: anecortave acetate | Phase III |
MedlinePlus related topics: Macular Degeneration
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: An evaluation of safety and efficacy of Anecortave Acetate versus placebo in patients with subfoveal choroidal neovascularization due to exudative age-related macular degeneration.
Eligibility
Ages Eligible for Study: 50 Years and above, Genders Eligible for Study: Both
Criteria
Location and Contact Information
Europe, ; Recruiting
New Zealand, ; Recruiting
More Information
Record last reviewed: January 2003
Last Updated: January 6, 2003
Record first received: January 3, 2003
ClinicalTrials.gov Identifier: NCT00051129
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Lunelle (Drug Digest)
- Medroxyprogesterone acetate and Estradiol cypionate injection (Drug Digest)

Not Signed In -


